Clinical Trials Information
As a biopharmaceutical company, Nektar Therapeutics conducts preclinical and clinical studies of our investigational medicines to evaluate them for both safety and efficacy. We focus our efforts on medical conditions where currently approved medicines are not providing optimal therapeutic benefit.
Before a new therapy can be made available to the general public, rigorous tests involving multiple studies on human volunteers are required. These studies, referred to as clinical trials, are carefully conducted and regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide. Participation in clinical trials allows patients to potentially gain access to the latest investigational treatments at little to no cost, and play a vital role in advancing medicine.
Nektar Therapeutics is currently recruiting patients in the U.S. and other countries for the following clinical trials. Please follow the links below for more information on the enrollment criteria for each study and site location:
Information for all NKTR-181 studies on clinicaltrials.gov
ONZEALD™ (etirinotecan pegol)
Information for all etirinotecan pegol studies on clinicaltrials.gov
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) or Anti-PD1 (Pembrolizumab) in Patients With Advanced Melanoma, Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer (PROPEL)
NKTR-214 Phase 1/2 Trial Sites
Further information and background on clinical trials may be found on www.clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH).